Defunct Company
Total Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
1,497
NCT01478178
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 31, 2011
Completion: Oct 31, 2016
NCT02717962
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Phase: Phase 2
Start: Jan 20, 2017
Completion: Dec 30, 2024
NCT03050736
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Start: Dec 17, 2017
NCT03970447
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Phase: Phase 2/3
Role: Collaborator
Start: Jul 30, 2019
Completion: Jun 30, 2030
NCT05374915
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
Start: Feb 12, 2024
Completion: Dec 31, 2025